TrialThe Journal of urology2012

Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.

Evan Y Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.